CoChat
Sign Up
Cited by 423

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches

Amidon, Seth, Brown, Jack E., Dave, Vivek S.·2015·AAPS PharmSciTech
DOI 10.1208/s12249-015-0350-9
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1208/s12249-015-0350-9

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 78

  1. Das S, Deshmukh R, Jha A. Role of natural polymers in the development of multiparticulate systems for colon drug targeting. Syst Rev Pharmacy. 2010;1(1):79–85. · DOI
  2. Leuva VR, Patel BG, Chaudhary DJ, Patel JN, Modasiya MMK. Oral colon-specific drug delivery system. J Pharm Res. 2012;5(4):2293–7.
  3. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J. 2010;25(2):79–87. · DOI · Paper page
  4. Kumar P, Mishra B. Colon targeted drug delivery systems—an overview. Curr Drug Deliv. 2008;5(3):186–98. · DOI
  5. Malayandi R, Kondamudi P, Ruby PK, Aggarwal D. Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease. Drug Deliv Transl Res. 2014;4(2):187–202. · DOI
  6. Coupe AJ, Davis SS, Wilding IR. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res. 1991;8(3):360–4. · DOI · Paper page
  7. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res. 1990;7(7):756–61. · DOI
  8. Ibekwe VC, Fadda HM, McConnell EL, Khela MK, Evans DF, Basit AW. Interplay between intestinal pH, transit time and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 2008;25(8):1828–35. · DOI · Paper page
  9. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos. 1990;11(6):465–75. · DOI
  10. Hebden JM, Blackshaw PE, Perkins AC, Wilson CG, Spiller RC. Limited exposure of the healthy distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther. 2000;14(2):155–61. · DOI
  11. Rana SV, Sharma S, Malik A, Kaur J, Prasad KK, Sinha SK, et al. Small intestinal bacterial overgrowth and orocecal transit time in patients of inflammatory bowel disease. Dig Dis Sci. 2013;58(9):2594–8. · DOI
  12. Stubbs JB, Valenzuela GA, Stubbs CC, Croft BY, Teates CD, Plankey MW, et al. A noninvasive scintigraphic assessment of the colonic transit of nondigestible solids in man. J Nucl Med. 1991;32(7):1375–81.
  13. Christl SU, Scheppach W. Metabolic consequences of total colectomy. Scand J Gastroenterol Suppl. 1997;222:20–4. · DOI
  14. Sandle GI. Salt and water absorption in the human colon: a modern appraisal. Gut. 1998;43(2):294–9. · DOI
  15. Schiller C, Frohlich CP, Giessmann T, Siegmund W, Monnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22(10):971–9. · DOI
  16. Shameem M, Katori N, Aoyagi N, Kojima S. Oral solid controlled release dosage forms: role of GI-mechanical destructive forces and colonic release in drug absorption under fasted and fed conditions in humans. Pharm Res. 1995;12(7):1049–54. · DOI
  17. Pijper A, Discombe G. Shape and motility of bacteria. J Pathol Bacteriol. 1946;58(3):325–42. · DOI
  18. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH. pH-profile and regional transit times of the normal gut measured by a radiotelemetry device. Aliment Pharmacol Ther. 1989;3(6):605–13. · DOI
  19. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. J Appl Bacteriol. 1992;72(1):57–64.
  20. Bown RL, Gibson JA, Sladen GE, Hicks B, Dawson AM. Effects of lactulose and other laxatives on ileal and colonic pH as measured by a radiotelemetry device. Gut. 1974;15(12):999–1004. · DOI
  21. Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 2001;48(4):571–7. · DOI
  22. Gibson SA, McFarlan C, Hay S, MacFarlane GT. Significance of microflora in proteolysis in the colon. Appl Environ Microbiol. 1989;55(3):679–83. · DOI
  23. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metab Rev. 1988;19(3–4):243–61. · DOI · Paper page
  24. Chung KT, Fulk GE, Egan M. Reduction of azo dyes by intestinal anaerobes. Appl Environ Microbiol. 1978;35(3):558–62. · DOI
  25. Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151–65. · DOI
  26. Ratner BD, Gladhill KW, Horbett TA. Analysis of in vitro enzymatic and oxidative degradation of polyurethanes. J Biomed Mater Res. 1988;22(6):509–27. · DOI
  27. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. Int J Pharm. 2001;224(1–2):19–38. · DOI · Paper page
  28. Kang M, Khanal T, Kim H, Lee D, Yeo H, Lee Y, et al. Role of metabolism by human intestinal microflora in geniposide-induced toxicity in HepG2 cells. Arch Pharm Res. 2012;35(4):733–8. · DOI
  29. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35–49. · DOI
  30. Azadkhan AK, Truelove SC, Aronson JK. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol. 1982;13(4):523–8. · DOI
  31. Hamedani R, Feldman RD, Feagan BG. Drug development in inflammatory bowel disease: budesonide-a model of targeted therapy. Aliment Pharmacol Ther. 1997;3:98–107. · DOI
  32. French DL, Mauger JW. Evaluation of the physicochemical properties and dissolution characteristics of mesalamine: relevance to controlled intestinal drug delivery. Pharm Res. 1993;10(9):1285–90. · DOI
  33. Nicholls A, Harris-Collazo R, Huang M, Hardiman Y, Jones R, Moro L. Bioavailability profile of Uceris MMX extended-release tablets compared with Entocort EC capsules in healthy volunteers. J Int Med Res. 2013;41(2):386–94. · DOI
  34. Rabito MF, Reis AV, Freitas Ados R, Tambourgi EB, Cavalcanti OA. A pH/enzyme-responsive polymer film consisting of Eudragit® FS 30 D and arabinoxylane as a potential material formulation for colon-specific drug delivery system. Pharm Dev Technol. 2012;17(4):429–36. · DOI
  35. Friend DR, Chang GW. A colon-specific drug-delivery system based on drug glycosides and the glycosidases of colonic bacteria. J Med Chem. 1984;27(3):261–6. · DOI
  36. Friend DR, Chang GW. Drug glycosides: potential prodrugs for colon-specific drug delivery. J Med Chem. 1985;28(1):51–7. · DOI
  37. Kim D, Hong S, Jung S, Jung Y, Kim YM. Synthesis and evaluation of N-nicotinoyl-2-{2-(2-methyl-5-nitroimidazol-1-yl)ethyloxy}-D,L-glycine as a colon-specific prodrug of metronidazole. J Pharm Sci. 2009;98(11):4161–9. · DOI
  38. Kim H, Lee Y, Yoo H, Kim J, Kong H, Yoon JH, et al. Synthesis and evaluation of sulfate conjugated metronidazole as a colon-specific prodrug of metronidazole. J Drug Target. 2012;20(3):255–63. · DOI
  39. Modasiya MK, Patel VM. Design of colon specific drug delivery using sodium alginate and HPMC. J Pharm Res. 2012;5(4):2253–8.
  40. Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr. 1987;45(5 Suppl):1243–55. · DOI · Paper page
  41. Scheline RR. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol Rev. 1973;25(4):451–523. · DOI
  42. Roos AA, Edlund U, Sjoberg J, Albertsson AC, Stalbrand H. Protein release from galactoglucomannan hydrogels: influence of substitutions and enzymatic hydrolysis by beta-mannanase. Biomacromolecules. 2008;9(8):2104–10. · DOI
  43. Hita V, Singh R, Jain SK. Colonic targeting of metronidazole using azo aromatic polymers: development and characterization. Drug Deliv. 1997;4(1):19–22. · DOI
  44. Ahmad MZ, Akhter S, Ahmad I, Singh A, Anwar M, Shamim M, et al. In vitro and in vivo evaluation of Assam Bora rice starch-based bioadhesive microsphere as a drug carrier for colon targeting. Expert Opin Drug Deliv. 2012;9(2):141–9. · DOI
  45. Alvarez-Fuentes J, Fernández-Arévalo M, González-Rodríguez ML, Cirri M, Mura P. Development of enteric-coated timed-release matrix tablets for colon targeting. J Drug Target. 2004;12(9/10):607–12. · DOI
  46. Fukui E, Miyamura N, Uemura K, Kobayashi M. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm. 2000;204(1–2):7–15. · DOI
  47. Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayed-release system for colonic specific delivery. Int J Pharm. 1994;108(1):77–83. · DOI
  48. Chourasia MK, Jain SK. Design and development of multiparticulate system for targeted drug delivery to colon. Drug Deliv. 2004;11(3):201–7. · DOI
  49. Hardy JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol. 1985;37(12):874–7. · DOI
  50. Vaidya A, Jain A, Khare P, Agrawal RK, Jain SK. Metronidazole loaded pectin microspheres for colon targeting. J Pharm Sci. 2009;98(11):4229–36. · DOI
  51. Perera G, Barthelmes J, Bernkop-Schnurch A. Novel pectin-4-aminothiophenole conjugate microparticles for colon-specific drug delivery. J Control Release. 2010;145(3):240–6. · DOI
  52. Ye L, Hong Z. Budesonide-loaded guar gum microspheres for colon delivery: preparation, characterization and in vitro/in vivo evaluation. Int J Mol Sci. 2015;16(2):2693–704. · DOI
  53. Agarwal T, Narayana SNGH, Pal K, Pramanik K, Giri S, Banerjee I. Calcium alginate-carboxymethyl cellulose beads for colon-targeted drug delivery. Int J Biol Macromol. 2015;75:409–17. · DOI
  54. Beloqui A, Coco R, Memvanga PB, Ucakar B, des Rieux A, Preat V. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Int J Pharm. 2014;473(1–2):203–12. · DOI
  55. Calabrese I, Cavallaro G, Scialabba C, Licciardi M, Merli M, Sciascia L, et al. Montmorillonite nanodevices for the colon metronidazole delivery. Int J Pharm. 2013;457(1):224–36. · DOI
  56. Spada G, Gavini E, Cossu M, Rassu G, Giunchedi P. Solid lipid nanoparticles with and without hydroxypropyl-beta-cyclodextrin: a comparative study of nanoparticles designed for colonic drug delivery. Nanotechnology. 2012;23(9). · DOI
  57. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Development of polysaccharide-based colon targeted drug delivery systems for the treatment of amoebiasis. Drug Dev Ind Pharm. 2007;33(3):255–64. · DOI
  58. Shukla RK, Tiwari A. Carbohydrate polymers: applications and recent advances in delivering drugs to the colon. Carbohydr Polym. 2012;88(2):399–416. · DOI
  59. Bassi P, Kaur G. pH modulation: a mechanism to obtain pH-independent drug release. Expert Opin Drug Deliv. 2010;7(7):845–57. · DOI
  60. Kosaraju SL. Colon targeted delivery systems: review of polysaccharides for encapsulation and delivery. Crit Rev Food Sci Nutr. 2005;45(4):251–8. · DOI
  61. Liu L, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003;24(19):3333–43. · DOI
  62. Wakerly Z, Fell JT, Attwood D, Parkins D. Studies on drug release from pectin/ethylcellulose film-coated tablets: a potential colonic delivery system. Int J Pharm. 1997;153(2):219–24. · DOI
  63. Maroni A, Zema L, Loreti G, Palugan L, Gazzaniga A. Film coatings for oral pulsatile release. Int J Pharm. 2013;457(2):362–71. · DOI · Paper page
  64. Obitte N, Chukwu A. The synergistic effect of Landolphia owariensis latex and Eudragit L-100-coated capsules on the in vitro controlled release of metronidazole for possible colon targeting. Asian J Pharm. 2011;5(2):75–83. · DOI
  65. Leopold CS, Eikeler D. Eudragit E as coating material for the pH-controlled drug release in the topical treatment of inflammatory bowel disease (IBD). J Drug Target. 1998;6(2):85–94. · DOI
  66. Yassin AE, Alsarra IA, Alanazi FK, Al-Mohizea AM, Al-Robayan AA, Al-Obeed OA. New targeted-colon delivery system: in vitro and in vivo evaluation using X-ray imaging. J Drug Target. 2010;18(1):59–66. · DOI
  67. Kadiyam R, Muzib YI. Colon specific drug delivery of tramadol HCl for chronotherapeutics of arthritis. Int J Pharm Investig. 2015;5(1):43–9. · DOI
  68. Maroni A, Del Curto MD, Cerea M, Zema L, Foppoli A, Gazzaniga A. Polymeric coatings for a multiple-unit pulsatile delivery system: preliminary study on free and applied films. Int J Pharm. 2013;440(2):256–63. · DOI
  69. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release. 1995;35(1):1–21. · DOI
  70. Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release. 2002;79(1–3):7–27. · DOI
  71. Sethi S, Harikumar SL, Nirmala. Review on advances in colon targeted drug delivery system. Int J Pharm Sci Res. 2012;3(9):2989–3000.
  72. Takaya T, Niwa K, Muraoka M, Ogita I, Nagai N, Yano R-i, et al. Importance of dissolution process on systemic availability of drugs delivered by colon delivery system. J Control Release. 1998;50(1–3):111–22. · DOI
  73. Hay DJ, Sharma H, Irving MH. Spread of steroid-containing foam after intrarectal administration. Br Med J. 1979;1(6180):1751–3. · DOI
  74. Philip AK, Pathak K. Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility. AAPS PharmSciTech. 2006;7(3):56. · DOI
  75. Abraham S, Srinath M. Development of modified pulsincap drug delivery system of metronidazole for drug targeting. Indian J Pharm Sci. 2007;69(1):24–7. · DOI
  76. Krogel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res. 1998;15(3):474–81. · DOI
  77. Huanbutta K, Sriamornsak P, Luangtana-Anan M, Limmatvapirat S, Puttipipatkhachorn S, Lim LY, et al. Application of multiple stepwise spinning disk processing for the synthesis of poly(methyl acrylates) coated chitosan-diclofenac sodium nanoparticles for colonic drug delivery. Eur J Pharm Sci. 2013;50(3–4):303–11. · DOI
  78. Marieb EN, Hoehn K. Human anatomy and physiology. 7th ed. San Francisco: Pearson Benjamin Cummings; 2007.

Cited by

Sorted by citations

Metadata

Authors
Amidon, S., Brown, J. E., & Dave, V. S.
Venue
AAPS PharmSciTech
Publisher
Springer Science and Business Media LLC
Published
2015-06-13
Volume
16
Issue
4
Pages
731-741
ISSN
1530-9932
DOI
10.1208/s12249-015-0350-9
Cited by
423
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review